Oramed Pharmaceuticals (NASDAQ:ORMP) Rating Increased to Hold at StockNews.com

Oramed Pharmaceuticals (NASDAQ:ORMP - Get Free Report) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Friday.

Separately, HC Wainwright reaffirmed a "neutral" rating on shares of Oramed Pharmaceuticals in a research report on Monday, September 9th.

Oramed Pharmaceuticals Trading Up 0.4 %

ORMP traded up $0.01 during midday trading on Friday, hitting $2.37. The company's stock had a trading volume of 126,390 shares, compared to its average volume of 139,027. Oramed Pharmaceuticals has a 52-week low of $2.00 and a 52-week high of $3.67. The firm has a 50-day moving average price of $2.37 and a two-hundred day moving average price of $2.40. The firm has a market cap of $95.54 million, a P/E ratio of 21.55 and a beta of 1.70.

Institutional Investors Weigh In On Oramed Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its holdings in shares of Oramed Pharmaceuticals by 52.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 31,470 shares of the biotechnology company's stock worth $81,000 after purchasing an additional 10,774 shares during the period. Renaissance Technologies LLC increased its position in Oramed Pharmaceuticals by 89.0% during the 2nd quarter. Renaissance Technologies LLC now owns 230,800 shares of the biotechnology company's stock worth $593,000 after purchasing an additional 108,700 shares in the last quarter. XTX Topco Ltd purchased a new position in Oramed Pharmaceuticals in the second quarter valued at approximately $40,000. Murchinson Ltd. lifted its position in Oramed Pharmaceuticals by 23.2% during the second quarter. Murchinson Ltd. now owns 1,699,990 shares of the biotechnology company's stock valued at $4,369,000 after buying an additional 320,495 shares in the last quarter. Finally, BML Capital Management LLC grew its stake in Oramed Pharmaceuticals by 62.1% during the third quarter. BML Capital Management LLC now owns 2,186,191 shares of the biotechnology company's stock worth $5,334,000 after buying an additional 837,153 shares during the period. Hedge funds and other institutional investors own 12.73% of the company's stock.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes.